Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Syros Pharmaceuticals (NQ: SYRS )

5.540 +0.090 (+1.65%)
Streaming Delayed Price Updated: 12:52 PM EDT, May 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Syros Pharmaceuticals

< Previous 1 2 3 4 5 6 Next >
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
  
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Investors can start off the day with a breakdown of the biggest pre-market stock movers for Tuesday and the news moving those shares! 
Via InvestorPlace
Why SeaChange International Is Trading Higher By Around 15%; Here Are 26 Stocks Moving Premarket
Gainers Comera Life Sciences Holdings, Inc. (NASDAQ: CMRA) rose 41.7% to $2.72 in pre-market trading. Comera Life Sciences Form 4 filing showed multiple insiders purchased 122,600 shares at an average... 
Via Benzinga
TYME Technologies Shares Surge On Merger Agreement With Syros Pharma
Via Benzinga
Syros Pharmaceuticals: Q1 Earnings Insights
Syros Pharmaceuticals (NASDAQ:SYRS) reported its Q1 earnings results on Monday, May 16, 2022 at 07:30 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Earnings Scheduled For May 16, 2022
Companies Reporting Before The Bell • AcelRx Pharmaceuticals (NASDAQ:ACRX) is estimated to report quarterly loss at $0.06 per share on revenue of $550.00 thousand. 
Via Benzinga
What 4 Analyst Ratings Have To Say About Syros Pharmaceuticals
  Analysts have provided the following ratings for Syros Pharmaceuticals (NASDAQ:SYRS) within the last quarter: 
Via Benzinga
Coinbase To $115? Plus This Analyst Cuts PT On Syros Pharmaceuticals By 67%
Deutsche Bank boosted the price target on FactSet Research Systems Inc. (NYSE: FDS) from $418 to $463. However, Deutsche Bank analyst Faiza Alwy maintained the stock with a Hold rating. FactSet... 
Via Benzinga
Citigroup Slashes Price Target On This Stock By 83%; Also Check Out Some Other Big PT Changes
RBC Capital cut the price target for Nuvei Corporation (NASDAQ: NVEI) from $80 to $60. Nuvei shares fell 21.5% to close at $33.03 on Tuesday. 
Via Benzinga
Biotech Daily: Regulatory Setback For CorMedix, Mersana & GSK In Cancer Pact, BARDA Funding For Opioid Overdose Hopeful
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Earnings Scheduled For August 9, 2022
Companies Reporting Before The Bell • Cognition Therapeutics (NASDAQ:CGTX) is estimated to report earnings for its second quarter. 
Via Benzinga
Why NanoViricides Jumped Over 48%; Here Are 106 Biggest Movers From Yesterday
Gainers ChemoCentryx, Inc. (NASDAQ: CCXI) surged 109.2% to settle at $50.43 on Thursday after the company, and Amgen, announced an agreement under which Amgen will acquire the company for $52 per share... 
Via Benzinga
Why ChemoCentryx Is Trading Higher By 110%, Here Are 95 Stocks Moving In Thursday's Mid-Day Session
Gainers InVivo Therapeutics Holdings Corp. (NASDAQ: NVIV) shares jumped 178.5% to $12.45 after gaining over 12% on Wednesday. 
Via Benzinga
Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers 
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Passage Bio (NASDAQ:PASG) shares moved upwards by 7.7% to $2.66 during Friday's after-market session. The market value of their outstanding shares is at $144.4 million. 
Via Benzinga
Why Is Yellow Trading Higher By 33%: Here Are 48 Stocks Moving Premarket
Gainers Missfresh Limited (NASDAQ: MF) shares rose 112.9% to $0.2450 in pre-market trading after dropping 7% on Wednesday. 
Via Benzinga
The Daily Biotech Pulse: AstraZeneca Goes Shopping, TYME Technologies & Syros Pharma Merger, FDA Clears Vertex Pharma's Stem Cell-Based Diabetes Therapy Study
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Syros Pharmaceuticals Earnings Perspective: Return On Capital Employed
Syros Pharmaceuticals (NASDAQ:SYRS) brought in sales totaling $5.47 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 5.6%, resulting in a loss of $25.15... 
Via Benzinga
10 Biggest Price Target Changes For Tuesday
Citigroup cut the price target on Insulet Corporation (NASDAQ: PODD) from $350 to $310. Insulet shares fell 1.1% to close at $196.91 on Monday. 
Via Benzinga
The Week Ahead In Biotech: Gene & Cell Therapy Conference, Tapering Earnings News, OKYO Pharma IPO And More
Biopharma stocks remained largely unchanged in the week ending May 13, with the defensive nature of the sector coming to its aid. Stocks reacted to the broader market move and earnings news from... 
Via Benzinga
Earnings Preview For Syros Pharmaceuticals
Syros Pharmaceuticals (NASDAQ:SYRS) is set to give its latest quarterly earnings report on Monday, 2022-05-16. Here's what investors need to know before the announcement. Analysts estimate that Syros... 
Via Benzinga
66 Biggest Movers From Yesterday
Gainers Better Therapeutics, Inc. (NASDAQ: BTTX) shares surged 120.4% to close at $2.01 on Monday following a 5% drop on Friday. SoundHound AI, Inc. (NASDAQ: SOUN) shares surged... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
60 Biggest Movers From Yesterday
Gainers Nkarta, Inc. (NASDAQ: NKTX) shares climbed 140.9% to close at $18.72 on Monday after the company announced Phase 1 data from independent dose finding studies of its two... 
Via Benzinga
Syros' CDK12 Inhibitor Shows Anti Tumor Activity In Preclinical Studies
Syros Pharmaceuticals Inc (NASDAQ: SYRS)  
Via Benzinga
Syros Pharmaceuticals Earnings Perspective: Return On Capital Employed
According to Benzinga Pro data, during Q4, Syros Pharmaceuticals (NASDAQ:SYRS) posted sales of $7.80 million. Earnings were up 8.51%, but Syros Pharmaceuticals still reported an... 
Via Benzinga
55 Biggest Movers From Friday
Gainers Vallon Pharmaceuticals, Inc. (NASDAQ: VLON) shares jumped 100.9% to close at $2.27 on Friday. Vallon Pharmaceuticals engaged Ladenburg Thalmann & Co Inc to evaluate... 
Via Benzinga
Recap: Syros Pharmaceuticals Q4 Earnings
Syros Pharmaceuticals (NASDAQ:SYRS) reported its Q4 earnings results on Tuesday, March 15, 2022 at 07:30 AM. Here's what investors need to know about the announcement.... 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.